Novel nanomedicine-based MRI contrast agents for gynecological malignancies

Gynecological cancers result in significant morbidity and mortality in women despite advances in treatment and diagnosis. This is due to detection of the disease in the late stages following metastatic spread in which treatment options become limited and may not result in positive outcomes. In addit...

Full description

Saved in:
Bibliographic Details
Published inAdvanced drug delivery reviews Vol. 61; no. 10; pp. 795 - 807
Main Authors Mody, Vicky V., Nounou, Mohamed Ismail, Bikram, Malavosklish
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 10.08.2009
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Gynecological cancers result in significant morbidity and mortality in women despite advances in treatment and diagnosis. This is due to detection of the disease in the late stages following metastatic spread in which treatment options become limited and may not result in positive outcomes. In addition, traditional contrast agents are not very effective in detecting primary metastatic tumors and cells due to a lack of specificity and sensitivity of the diagnostic tools, which limits their effectiveness. Recently, the field of nanomedicine-based contrast agents offers a great opportunity to develop highly sophisticated devices that can overcome many traditional hurdles of contrast agents including solubility, cell-specific targeting, toxicities, and immunological responses. These nanomedicine-based contrast agents including liposomes, micelles, dendrimers, multifunctional magnetic polymeric nanohybrids, fullerenes, and nanotubes represent improvements over their traditional counterparts, which can significantly advance the field of molecular imaging.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0169-409X
1872-8294
DOI:10.1016/j.addr.2009.04.020